Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease

被引：6

作者：

Yau, Kevin ^{[1
,2
]}

Kurtesi, Alexandra ^{[3
]}

Qi, Freda ^{[3
]}

Delgado-Brand, Melanie ^{[3
]}

Tursun, Tulunay R. ^{[3
]}

Hu, Queenie ^{[3
]}

Dhruve, Miten ^{[4
]}

Kandel, Christopher ^{[5
]}

Enilama, Omosomi ^{[6
]}

Levin, Adeera ^{[7
]}

Jiang, Yidi ^{[8
]}

Hardy, W. Rod ^{[3
]}

Yuen, Darren A. ^{[9
]}

Perl, Jeffrey ^{[9
]}

Chan, Christopher T. ^{[2
]}

Leis, Jerome A. ^{[10
]}

Oliver, Matthew J. ^{[1
,11
]}

Colwill, Karen ^{[3
]}

Gingras, Anne-Claude ^{[3
,12
]}

Hladunewich, Michelle A. ^{[1
,11
]}

机构：

[1] Univ Toronto, Temerty Fac Med, Sunnybrook Hlth Sci Ctr, Div Nephrol,Dept Med, Toronto, ON, Canada

[2] Univ Toronto, Univ Hlth Network, Temerty Fac Med, Div Nephrol,Dept Med, Toronto, ON, Canada

[3] Sinai Hlth, Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada

[4] Michael Garron Hosp, Div Nephrol, Toronto, ON, Canada

[5] Michael Garron Hosp, Div Infect Dis, Toronto, ON, Canada

[6] Univ British Columbia, Div Expt Med, Dept Med, Vancouver, BC, Canada

[7] British Columbia Prov Renal Agcy, Vancouver, BC, Canada

[8] Sunnybrook Res Inst, Ctr Clin Trial Support, Toronto, ON, Canada

[9] Univ Toronto, Temerty Fac Med, Dept Med, Div Nephrol,Unity Hlth Toronto, Toronto, ON, Canada

[10] Univ Toronto, Temerty Fac Med, Sunnybrook Hlth Sci Ctr, Dept Med,Div Infect Dis, Toronto, ON, Canada

[11] Ontario Renal Network, Toronto, ON, Canada

[12] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada

来源：

NATURE COMMUNICATIONS | 2023年 / 14卷 / 01期

基金：

加拿大健康研究院; 加拿大创新基金会;

关键词：

D O I：

10.1038/s41467-023-41678-9

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Neutralization of Omicron subvariants by different bivalent vaccines has not been well evaluated. This study characterizes neutralization against Omicron subvariants in 98 individuals on dialysis or with a kidney transplant receiving the BNT162b2 (BA.4/BA.5) or mRNA-1273 (BA.1) bivalent COVID-19 vaccine. Neutralization against Omicron BA.1, BA.5, BQ.1.1, and XBB.1.5 increased by 8-fold one month following bivalent vaccination. In comparison to wild-type (D614G), neutralizing antibodies against Omicron-specific variants were 7.3-fold lower against BA.1, 8.3-fold lower against BA.5, 45.8-fold lower against BQ.1.1, and 48.2-fold lower against XBB.1.5. Viral neutralization was not significantly different by bivalent vaccine type for wild-type (D614G) (P = 0.48), BA.1 (P = 0.21), BA.5 (P = 0.07), BQ.1.1 (P = 0.10), nor XBB.1.5 (P = 0.10). Hybrid immunity conferred higher neutralizing antibodies against all Omicron subvariants. This study provides evidence that BNT162b2 (BA.4/BA.5) and mRNA-1273 (BA.1) induce similar neutralization against Omicron subvariants, even when antigenically divergent from the circulating variant. Here the authors evaluate neutralizing antibodies following COVID-19 bivalent vaccination and find that both Pfizer BA.5 (BNT162b2) and Moderna BA.1 (mRNA-1273) vaccines elicit similar neutralization against Omicron subvariants BA.1, BA.5, BQ.1.1, and XBB.1.5 in patients with end-stage kidney disease.

引用

页数：8

共 50 条

[21] Omicron Variant-Specific Serological Imprinting Following BA.1 or BA.4/5 Bivalent Vaccination and Previous SARS-CoV-2 Infection: A Cohort Study
Baerends, Eva A. M.
Reekie, Joanne
Andreasen, Signe R.
Staerke, Nina B.
Raben, Dorthe
Nielsen, Henrik
Petersen, Kristine T.
Johansen, Isik S.
Lindvig, Susan O.
Madsen, Lone W.
Wiese, Lothar
Iversen, Mette B.
Benfield, Thomas
Iversen, Kasper K.
Larsen, Fredrikke D.
Andersen, Sidsel D.
Juhl, Anna K.
Dietz, Lisa L.
Hvidt, Astrid K.
Ostrowski, Sisse R.
Krause, Tyra G.
ostergaard, Lars
Sogaard, Ole S.
Lundgren, Jens
Tolstrup, Martin
CLINICAL INFECTIOUS DISEASES, 2023, 77 (11) : 1511 - 1520
[22] Comparative Effectiveness of the Bivalent (Original/Omicron BA.4/BA.5) mRNA COVID-19 Vaccines mRNA-1273.222 and BNT162b2 Bivalent in Adults with Underlying Medical Conditions in the United States
Kopel, Hagit
Nguyen, Van Hung
Bogdanov, Alina
Winer, Isabelle
Boileau, Catherine
Ducruet, Thierry
Zeng, Ni
Winer-Jones, Jessamine P.
Esposito, Daina B.
Bausch-Jurken, Mary
Beck, Ekkehard
Bonafede, Machaon
Mansi, James A.
VACCINES, 2024, 12 (10)
[23] A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in ≥12-Year-Olds
Usdan, Lisa
Patel, Sohil
Rodriguez, Hector
Xu, Xia
Lee, Dung-Yang
Finn, Daniel
Wyper, Hayley
Lowry, Francine S.
Mensa, Federico J.
Lu, Claire
Cooper, David
Koury, Kenneth
Anderson, Annaliesa S.
Tureci, Ozlem
Sahin, Ugur
Swanson, Kena A.
Gruber, William C.
Kitchin, Nicholas
CLINICAL INFECTIOUS DISEASES, 2024, 78 (05) : 1194 - 1203
[24] Comparative immunogenicity of original/BA.4/BA.5-adapted bivalent BNT162b2 MRNA vaccine and the bivalent PHH-1V recombinant protein as a fourth dose
Darnaude Ximenez, I.
Diez Fuentes, F.
Deulofeu, M.
Bermejo, M.
Vicente, L.
Aparicio, M.
Ferrer, L.
Avendano Sola, C.
Perez Olmeda, M.
Garcia Perez, J.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2024, 135 : 37 - 37
[25] Protection against Omicron BA.1/BA.2 severe disease 0–7 months after BNT162b2 booster
Ofra Amir
Yair Goldberg
Micha Mandel
Yinon M. Bar-On
Omri Bodenheimer
Laurence Freedman
Sharon Alroy-Preis
Nachman Ash
Amit Huppert
Ron Milo
Communications Biology, 6
[26] The breadth and neutralizing activity of SARS-CoV-2 antibodies among children 6 months to 4 years of age following vaccination with mRNA-1273 or BNT162b2
Williams, Caitlin
Dalapat, Trisha
Giorgi, Elena
Hurst, Jillian
Herbek, Savannah
Chen, Jui-Lin
Kosman, Christina
Rotta, Alexandre
Turner, Nicholas
Pulido, Natalie
Aquino, Jhoanna
Pfeiffe, Trevor
Rodriguez, Javier
Permar, Sallie
Fouda, Genevieve
Kelly, Matthew
JOURNAL OF IMMUNOLOGY, 2024, 212 (01):
[27] Antibody Response to Vaccination with BNT162b2, mRNA-1273, and ChADOx1 in Patients with Myeloid and Lymphoid Neoplasms
Rotterdam, Jil
Thiaucourt, Margot
Schwaab, Juliana
Reiter, Andreas
Kreil, Sebastian
Steiner, Laurenz
Popp, Henning D.
Hofmann, Wolf-Karsten
Bonatz, Karin
Gerhards, Catharina
Neumaier, Michael
Jawhar, Mohamad
Saussele, Susanne
BLOOD, 2021, 138
[28] Protection against Omicron BA.1/BA.2 severe disease 0-7 months after BNT162b2 booster
Amir, Ofra
Goldberg, Yair
Mandel, Micha
Bar-On, Yinon M.
Bodenheimer, Omri
Freedman, Laurence
Alroy-Preis, Sharon
Ash, Nachman
Huppert, Amit
Milo, Ron
COMMUNICATIONS BIOLOGY, 2023, 6 (01)
[29] COVID-19 Outbreak and BNT162b2 mRNA Vaccination Coverage in a Correctional Facility during Circulation of the SARS-CoV-2 Omicron BA.1 Variant in Italy
Stufano, Angela
Buonvino, Nicola
Trombetta, Claudia Maria
Pontrelli, Daniela
Marchi, Serena
Lobefaro, Giuseppe
De Benedictis, Leonarda
Lorusso, Eleonora
Carofiglio, Maria Teresa
Vasinioti, Violetta Iris
Montomoli, Emanuele
Decaro, Nicola
Lovreglio, Piero
VACCINES, 2022, 10 (07)
[30] Cytokine and Chemokine Production in Mice Inoculated with NVX-CoV2373 (Nuvaxovid®) in Comparison with Omicron BA.4/5 Bivalent BNT162b2 (Comirnaty®)
Nakayama, Tetsuo
Ito, Takashi
Ishiyama, Ryoka
Katayama, Kazuhiko
VACCINES, 2023, 11 (11)

← 1 2 3 4 5 →